Galena presentation 13 sept 16

1. HEMATOLOGY &
ONCOLOGY FOCUSED
COMPANY
September 13, 2016

2. FORWARD LOOKING STATEMENT
This presentation contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements include, but are
not limited to, statements about future expectations, plans and prospects for the
development and commercialization of the Company's product candidates,
including patient enrollment in our clinical trials, present or future licensing,
collaborative or financing arrangements, expected outcomes with regulatory
agencies, and projected market opportunities for product candidates are subject
to a number of risks, uncertainties and assumptions, including those identified
under “Risk Factors” in the Company’s most recently filed Annual Report on Form
10-K and Quarterly Report on Form 10-Q and in other filings the
Company periodically makes with the SEC. Actual results may differ materially
from those contemplated by these forward-looking statements. The
Company does not undertake to update any of these forward-looking statements
to reflect a change in its views or events or circumstances that occur after the
date of this presentation.
2

3. TARGETING AREAS OF UNMET MEDICAL
NEEDS
Hematology
GALE-401
• Proprietary controlled release
version of anagrelide
• Targeting 3rd Line Essential
Thrombocythemia (ET)
• Phase 3 initiation expected in
Q2, 2017
 Plan to develop under 505(b)2
pathway
Immunotherapy
NeuVax™ (nelipepimut-S)
• Development in key settings
 Combination with trastuzumab
in HER2 1+/2+
 Combination with trastuzumab
in HER2 3+
 DCIS
 Gastric
GALE-301/GALE-302
• Targeted development in
gynecological cancers
3
Committed to the development and commercialization of hematology and
oncology therapeutics that address unmet medical needs

4. DEVELOPMENT PIPELINE
PRODUCT THERAPETIC AREA PHASE 1 PHASE 2 PHASE 3 BLA / NDA
Hematology
GALE-401 (Anagrelide CR) Essential Thrombocythemia
Immunotherapy: Breast Cancer
NeuVax™ + Herceptin® Node-positive or node negative/triple
negative, HER2 IHC 1+/2+
NeuVax™ + Herceptin® High risk, node-positive or negative,
HER2 IHC 3+
NeuVax™ Ductal Carcinoma in Situ (DCIS)
Immunotherapy: Gastric Cancer
NeuVax™ Gastric, HER2 IHC 1+/2+/3+
Immunotherapy: Gynecological Cancer
GALE-301 Ovarian & Endometrial
GALE-301 + GALE-302 Ovarian & Breast
*NeuVax is an investigational product. Efficacy has not been established. Herceptin is a registered trademark of Genentech.
Ongoing Planned
VADIS
4
2b

5. GALE-401
Anagrelide Controlled
Release (CR)

6. ANAGRELIDE
 Anagrelide suppresses megakaryocytopoiesis by inhibiting PDE III-
dependent and PDE III-independent mechanisms
 No DNA damaging or cytotoxic effect
 Immediate release version Indicated for the treatment of patients with
thrombocythemia, secondary to myeloproliferative disorders to reduce the
elevated platelet count and the risk of thrombosis and to ameliorate
associated symptoms including thrombo-hemorrhagic events
 Approved to treat Myleoproliferative Neoplasms (MPNs) including Essential
Thrombocythemia (ET)
6

7. ANAGRELIDE IMMEDIATE RELEASE (IR) AEs
Related Adverse Events (AEs)
AGRYLINa
(n=942)
%
Cardiac 42
Generalc 83
Gastrointestinal 92
Respiratory, thoracic and mediastinal 18
Skin and subcutaneous tissue 14
Musculoskeletal and connective tissue 6
Nervous system 65
Vascular <5
Hepatobiliary <5
Blood and Lymphatic <5
Number of AEs/patient 3.3
a Anagrelide IR ADR data from the product label
c General AEs referred to fatigue, peripheral edema, and malaise
Most common
reasons for
discontinuation
Confidential 7
Sources: Harrison et al N Engl J Med 2005;353:33-45; Mehta et al, (2014) Epidemiology of myeloproliferative neoplasms in the United
States, Leukemia & Lymphoma, 55:3, 595-600, DOI: 10.3109/10428194.2013.813500; Agrylin is a registered trademark of Shire.
Approximately 25 – 30% of
patients are intolerant
to Anagrelide IR

8. GALE-401 PHASE 1 TRIALS: CR FORMULATION
MAINTAINS PLATELET LOWERING & REDUCES Cmax
8
Multiple Phase 1 studies in n=86 healthy volunteers; Agrylin is a registered trademark of Shire.
Anagrelide CR Plasma Levels
pg/mL
Anagrelide CR Platelet Lowering
 GALE-401 is a proprietary, controlled release formulation of anagrelide
• Lower peak plasma concentration
• Maintain the Area Under the Curve (AUC)

9. ESSENTIAL THROMBOCYTHEMIA (ET)
 ET is a neoplastic stem cell
disorder causing dysregulated
production of large numbers
of abnormal megakaryocytes
resulting in elevated platelets
 Up to 50% of patients may be
asymptomatic at presentation
 Associated with vascular
complications
• Increased risk of thrombosis and
cardiovascular events
• Patients older than 60 at greatest
risk of complications
9
Arrows:
Megakaryocytes
ET has Larger Number
of Megakayocytes
Source: Haematologica. 2009 June; 94(6): 865, Am J Hematology. 2008 May;83(5):359)

10. ESSENTIAL THROMBOCYTHEMIA (ET):
CURRENT U.S. STANDARD OF CARE
10
• Generally first line therapy for ET
• Cytotoxic Myelosuppressive drug (reduces
other blood cells as well)
• Increased risk of developing acute leukemia
after long term; avoided in younger patients
• About 25% of patients are
intolerant/refractory
• Off-label third line use
• Non cytotoxic drug
• Not used in most patients because requires
injection and is associated with flu like
symptoms
• Used mostly in pregnant women
• Generally second line therapy for ET
• Non cytotoxic drug
• Decreases platelets formation
• Not associated with increased risk of
leukemia
• Side effects: palpitations, headaches
• About one-third are intolerant to Anagrelide
IR
• Hydroxyurea and Anagrelide
Treatment Failure
Sources: Leukemia and Lymphoma Society: Essential Thrombocythemia Facts Cervantes, F. Hematology 2011; 215-221
1st Line: Hydroxyurea
2nd Line: Anagrelide IR
Interferon alpha
3rd Line: Unmet Need

11. GALE-401: TARGET PRODUCT PROFILE (TPP)
vs ANAGRELIDE IR
Confidential 11
Anagrelide IR
GALE-401
TPP
Comment
PK
• Half life
• Cmax
• 2-3 hours
• 4X GALE-401
• 20 hours
• 25% of IR
Improved PK profile
Safety
• Related TEAEs
• # of AE/Patient
• 42.1%
• 3.3
• 30%
• 2.3
Better tolerated
Onset of Action As early as 4 weeks As early as 1 week Faster onset of
benefit
Doses per day 2 to 4 times a day (Label:
starting at doses of 0.5-2.0 mg
every 6 hours)
Target: 1 a day 2 X day based on
PII
Targeting 1 X day in
PIII
Dose regiment (compliance) Dose
(mg) needed per day
2 to 10 mg a day Target: Mean 2 mg a day Potentially as result
of improved PK
Therapeutic window (distance
between therapeutic dose curve and
toxic dose)
Narrow (dose escalation
to optimal effect is
challenging)
Wider Possibility of
increasing the dose
to desired effect for
GALE-401

12. GALE-401 PHASE 2 STUDY SUPPORTS
TARGETING IR INTOLERANT POPULATION
0
50
100
150
200
250
6001 2002 9001
On IR On GALE-401
Mean 7days 106 days
Median 7days 75 days
Max 7days 196 days
Min 7days 47 days
Three patients that discontinued IR were
on GALE-401 for average of 106 days
Two IR intolerant patients were on
GALE-401 for 660 days and 450 days
0
200
400
600
800
1000
1200
1400
1600
2001 6005
On GALE-401
On IR
12

13. GALE-401 ET DEVELOPMENT OPPORTUNITY
Clinical Need
 Significant unmet medical need
• No approved therapies after
Anagrelide IR and Hydroxyurea
 Diagnosed ET patient population
• US Prevalence: 135,000 - 175,000
• An estimated 9,000 3rd line patients in
the US
 Chronic Disease
Development Path
 Advantageous development and
regulatory path: 505b(2)
 Limited competition with very few
agents in development
 Multiple life cycle management
opportunities
 Next steps
• Finalize the Phase 3 clinical trial
design
• End of Phase 2 FDA meeting
• Initiate pivotal trial in 2Q, 2017
13
Sources: Harrison et al N Engl J Med 2005;353:33-45; Mehta et al, (2014) Epidemiology of myeloproliferative
neoplasms in the United States, Leukemia & Lymphoma, 55:3, 595-600, DOI: 10.3109/10428194.2013.813500

14. NEUVAX™
(nelipepimut-S)
Targeting HER2

15. NEUVAX: HER2 IMMUNODOMINANT PEPTIDE
 NeuVax contains the
immunodominant peptide derived
from the extracellular region of the
HER2 protein
 Peptide (aa 369-377)
immunotherapy administered as
intradermal injection
 MHC Class I: HLA A2/A3
15
K I F G S L A F L

16. ELICITS A STRONG CD8+ T-CELL RESPONSE
 NeuVax binds to antigen
presenting cells (APCs)
 NeuVax stimulates APCs to
activate CD8+ cytotoxic T
lymphocytes (CTLs)
 CTLs rapidly replicate to seek out
and destroy HER2 expressing
tumor cells and micro-metastases
 Booster series maintains long
term immunologic response
 Demonstrated inter- and intra-
antigenic epitope spreading
16
Sources: Peoples GE, et al (2005) JCO, 23(300, 7536-7545; Mittendorf EA, et al
(2006) Surgery, 139(3): 407-418. Peoples, et al, ASCO 2012 Poster Presentation
0.4
1.8
0.7
0.5
0.0
0.5
1.0
1.5
2.0
2.5
%NeuVaxspecificCD8+Tcells
NeuVax Specific CD-8 CTLs: Pre-, Post, Mean and
Long-Term (6 months)
Pre Max Mean Long-Term

17. T-Cell
Activating Receptors Inhibitory Receptors
CD28
OX40
GITR
CD122
CD27
CD360
HVEM
CD137
CTLA-4
PD-1
TIM-3
BTLA
VISTA
LAG-3
IMMUNO-ONCOLOGY:
UNLOCKING THE POWER OF THE T-CELL
17
Checkpoint
inhibitors
Indirect Immune
Modulators
Co-stimulators
Immune Inhibitory
Enzymes

18. T-Cell
Activating Receptors Inhibitory Receptors
CD28
OX40
GITR
CD122
CD27
CD360
HVEM
CD137
CTLA-4
PD-1
TIM-3
BTLA
VISTA
LAG-3
LACK OF REACTIVE T-CELLS MAY RENDER SOME
TOOLS INEFFECTIVE IN MANY CANCERS
18
Checkpoint
inhibitors
Indirect Immune
Modulators
Co-stimulators
Immune Inhibitory
Enzymes

19. T-Cell
CD28
OX40
GITR
CD122
CD27
CD360
HVEM
CD137
CTLA-4
PD-1
TIM-3
BTLA
VISTA
LAG-3
Activating Receptors Inhibitory Receptors
OUR VACCINES STIMULATE T-CELL
PROLIFERATION AND EXPANSION
19
T
cells
Checkpoint
inhibitors
Indirect Immune
Modulators
Co-
stimulators
Immune
Inhibitory
Enzymes
T
cells
T
cells
T
cells
T
cells
T
cells
T
cells
T
cells
T
cells
T
cells
GALE-301
Trastuzamab

20. IMMUNO-ONCOLOGY: COMBINATION STRATEGY
20

21. CORRELATION BETWEEN HER2 & MHC-1
 There is an inverse
correlation between HER2
and MHC class I
 HER2 overexpression is
associated with decreased
expression of components
of the Ag processing/
presentation pathway
 Hypothesis: Trastuzumab
treatment will enhance
response to vaccination
 By making tumor cells
more visible to T-
cells/immune system.
21

22. COMBINATION IMMUNOTHERAPY ENHANCES
ANTIGEN PRESENTATION
Trastuzumab
HER2/neu
Breast
tumor cell
HER2/neu –derived peptide
presented on MHC-I
HER2/neu-
derived
peptide
Trastuzumab/HER2 complexes are
internalized and processed by proteasomes
into short peptides which are then presented
on MHC class I molecules.
Source: Mittendorf EA, et al (2006). Ann Surg Oncol;13:1085-98.
20.0
25.0
30.0
35.0
40.0
45.0
50.0
55.0
60.0
Average%Cytotoxicity51Cr
0 ug 10 ug 50 ug
* p=0.015
PBMC from HER2/neu peptide, E75,
vaccinated patients efficiently recognize and
lyse trastuzumab-treated HER2/neu-
expressing tumor cell lines
22

23. Interim
Analysis
at 1 Year DFS
Standard of Care: Standard Herceptin
dosing every 3 weeks for 1 year
6 doses of NeuVax given every 3 weeks
starting with third dose of Herceptin
+ 1 booster
dose every
6 months
thereafter
+ Dosing to disease
progression;
36 mo follow up
Primary
Endpoint
DFS at
24 mos.
300 adjuvant breast cancer
patients, randomized 1:1
 Single blind (subject)
 Node positive or high risk
node negative
 HLA A2/A3+
 HLA A24/A26+
 HER2 IHC 1+/2+
 Stratified by nodal status
and HER2 status
Study Population
NEUVAX+TRASTUZUMAB:
HER2 1+/2+ PHASE 2 STUDY
GM-CSF
+ GM-CSF
23

24. NEUVAX: CURRENT CLINICAL TRIALS
Phase Treatment
HER2
Status
Indication Trial Status
Protocol
Defined
# of Patients
Collaborations
2b
Combination
with
trastuzumab
1+, 2+
BREAST
Node Positive or High
Risk Node Negative
HLA A2+, A3+,
A24+, A26+
Enrolling
U.S. only
33 centers
300
2
Combination
with
trastuzumab
3+ high
risk
BREAST
Node Positive
HLA A2+, A3+
Enrolling
U.S. only
28 centers
100
2
Single agent
VADIS Study
1+,
2+,3+
BREAST
Ductal Carcinoma in
Situ (DCIS)
HLA A2+
Suspended
U.S. only
4 centers
48
2 Single agent
1+,
2+,3+
GASTRIC
HLA A2+, A3+
Planned
India Only
50
24

25. Targeting Folate Binding
Protein
GALE-301 &
GALE-302

26. GALE-301 & GALE-302
26Source: U.S. Ovarian Cancer http://seer.cancer.gov/statfacts/html/ovary.html
 Targeted cancer
immunotherapy
 Folate Binding Protein (FBP)
is over-expressed (20-80 fold)
in >90% of ovarian and
endometrial cancers
 FBP has very limited tissue
distribution and expression in
non-malignant tissue making it
an ideal immunotherapy target
 Current treatments are generic
• Carboplatin and paclitaxel
• High recurrence rate
 Most patients relapse with
poor prognosis

27. GALE-301: OPTIMAL DOSE GROUP SHOWS
PRELIMINARY EFFICACY
Source: Peoples, et. al, Poster Presentation, American Society of Clinical Oncology 2016 27
Phase 1/2a trial ongoing
 Phase 1: Determined optimal dose and
demonstrated safety and potent immune
response
 Phase 2a Preliminary data:
• At 16 months median follow-up:
 Overall recurrence rate was 44.8% in
the VG versus 54.5% in the CG
(p=0.58),
 Recurrence rate of 23.5% in patients
who received booster inoculations.
• Two year DFS estimate in 1000 mcg dose
group is 73.5% vaccine vs. 38.1% control
(p=.03)
• GALE-301 plus GM-CSF is well tolerated
and elicits a strong in vivo immune
response with primarily Grade 1 and
Grade 2 toxicities
Estimated 24 months Disease Free Survival by
Dosing Cohort

28. CORPORATE
OVERVIEW
28

29. LEADERSHIP TEAM
29
 Mark W. Schwartz, Ph.D.
President & CEO
Apthera, Bayhill Therapeutics, Calyx
Therapeutics, Trega Biosciences, Incyte
Genomics, DuPont Diagnostics
 Bijan Nejadnik, M.D.
Executive VP, Chief Medical Officer
Jazz Pharmaceuticals, Johnson & Johnson,
Stanford, Johns Hopkins, UC Davis
 Remy Bernarda,
SVP, Investor Relations & Corporate
Communications
IR Sense, Hana Biosciences, Knight Equity
Markets, Bear Stearns, Goldman Sachs
 John Burns, CPA
VP, Finance & Corporate Controller
Pixelworks, Moss Adams
 Tom Knapp, Esq.
Interim General Counsel
Sucampo, Exemplar Law Partners,
NorthWestern Energy, Paul Hastings, The
Boeing Company
 Joe Lasaga
VP, Business Development & Alliance
Management
Nektar Therapeutics, Rigel
Pharmaceuticals

30. FINANCIAL OVERVIEW
Cash Position (as of June 30, 2016) $19.6 million
Financing (July 13, 2016) + $11.7 million
Debt Financing (Amended Aug 22, 2016) + $24 million ($18.5M restricted cash)
Projected Quarterly Burn
Q3, 2016 $12 - $13 million
Q4, 2016 $8 - $10 million
Shares Outstanding (as of July 31, 2016) 214 million
Market Cap (as of September 8, 2016) ~$80 million
30

31. 2H, 2016 MILESTONES
31
PROGRAM MILESTONE
PROJECTED
DATE
GALE-401
(anagrelide CR)
Present combined P1 & P2 safety data ✓
Confirmation of 505(b)2 pathway 2H
Submit final Phase 2 report Q4
NeuVax™
(nelipepimut-S)
Fast Track Designation ✓
Initiate DCIS trial Q2
Combo H&N 1+/2+ Interim safety data Q4
GALE-301
GALE-302
Present 301/302 booster data ✓
Present GALE-301 Phase 2a primary analysis ✓
Orphan Drug Designation ✓
Present GALE-301 Biomarker & Dosing Data Q4

32. THANK YOU
NASDAQ: GALE